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Abstract
Improper design or use of blood collection devices can adversely affect the accuracy of laboratory test results. Vascular access devices, such as cathe-
ters and needles, exert shear forces during blood flow, which creates a predisposition to cell lysis. Components from blood collection tubes, such as 
stoppers, lubricants, surfactants, and separator gels, can leach into specimens and/or adsorb analytes from a specimen; special tube additives may 
also alter analyte stability. Because of these interactions with blood specimens, blood collection devices are a potential source of pre-analytical error 
in laboratory testing. Accurate laboratory testing requires an understanding of the complex interactions between collection devices and blood spe-
cimens. Manufacturers, vendors, and clinical laboratorians must consider the pre-analytical challenges in laboratory testing. Although other authors 
have described the effects of endogenous substances on clinical assay results, the effects/impact of blood collection tube additives and components 
have not been well systematically described or explained. This review aims to identify and describe blood collection tube additives and their compo-
nents and the strategies used to minimize their effects on clinical chemistry assays.
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Proper blood collection and timely processing are 
critical pre-analytical steps required for the integ-
rity of laboratory results. Although the influence of 
blood collection devices on laboratory tests is of-
ten overlooked, correct pre-analytical handling is 
essential. However, many laboratorians do not 
carefully evaluate the suitability of new devices or 
monitor ongoing performance. In this review, we 
discuss how blood collection materials and devic-
es can alter chemistry test results, with an empha-
sis on blood collection tube (BCT) additives.
Blood collection device history
Reusable glass syringes with steel hypodermic 
needles and a hard rubber hub were the first de-
vices used to collect blood (1). Early modifications 
included a refined needle, replacement of the rub-
ber hub with glass, and the Luer-Lok syringe, which 
modified the needle tip for a more secure attach-
ment to the syringe and ensuring a more reliable 
and safer drug delivery (1). Glass syringes were ex-
pensive to manufacture and were susceptible to 
breakage (2); nevertheless, what ultimately 
prompted their replacement with sterile disposa-
ble syringes (1) were the multiple hepatitis out-
breaks that resulted from their use (1). Modern 
chemical sterilization techniques and radiation al-
lowed the replacement of glass syringes by plastic 
syringes.
Since the 1940s, evacuated BCTs have been the 
most commonly used blood collection devices, 
since they automatically draw a predetermined 
blood volume and switching between tubes for 
additional samples poses a lower risk of spillage 
and needle-stick injury (3). Thus, the evolution of 
blood collection tubes have improved specimen 
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quality and workflow efficiency as well as the safe-
ty of patients and health care workers.
Glass evacuated tubes containing anticoagulants 
were commonly used from the 1950s to the 1990s 
(4). Presently, plastic has replaced glass, and poly-
mer gels and clot activators are common additives 
(5). Despite their similarity, evacuated tubes sup-
plied by different manufacturers vary in the mate-
rials and additives used, which can potentially af-
fect test performance (6). In the United States, 
there are two major manufacturers of evacuated 
tubes: Becton Dickinson (BD) (Franklin Lakes, NJ, 
USA) and Greiner Bio-One (Monroe, NC, USA).
Because BCTs function properly under most cir-
cumstances, many laboratorians are unaware of 
their complexity and limitations. A widespread 
surfactant (SF) problem revealed how these devic-
es can adversely affect laboratory test results (7,8) 
and emphasized the importance of understanding 
device limitations.
Blood collection tubes
BCTs consist of tube walls, rubber stoppers, lubri-
cants, anticoagulants, separator gels, clot activa-
tors, and SFs, all of which can affect the quality of 
the specimens, accuracy and precision of labora-
tory tests (Figure 1).
Tube walls
Evacuated BCTs are generally cylindrical, measur-
ing 50 mm to 150 mm in length and 10 mm to 20 
mm in diameter (9). Most tubes for adult clinical 
specimens are 75 mm to 100 mm in length and 13 
mm in diameter, and collect 2 to 10 mL of whole 
blood (9,10). Micro-collection tubes for pediatric 
specimens are 40 to 50 mm in length and 5 to 10 
mm in diameter (11). Evacuated tubes were origi-
nally made from soda-lime or borosilicate glass, 
but soda-lime tubes were found to release calcium 
and magnesium into blood specimens (12). Glass 
evacuated tubes are manufactured to be airtight, 
waterproof, and thermally resistant, which allows 
for vacuum preservation and long shelf lives (13). 
The contact of blood coagulation factors, such as 
Factor XII (Hagemann Factor), with hydrophilic 
glass surfaces activates the clotting cascade lead-
ing to the conversion of fibrinogen to fibrin, thus 
enabling the separation of the non-adherent clot 
from blood plasma by centrifugation (14). Howev-
er, clot re-suspension into plasma during handling 
or transport can interfere with assays attributable 
to the effects of hemolysis on test results (15,16).
Plastic tubes recently replaced most glass tubes 
following the establishment of the Occupational 
Safety and Health Administration (OSHA) guide-
lines to improve safety and reduce exposure to 
blood-borne pathogens (15). Plastic tubes are 
manufactured through injection-molding, using 
polyesters (e.g. polyethylene terephthalate (PET)), 
polyolefins (e.g. polyethylene and polypropylene 
(PP)), polyacrylic, polytetrafluoroethylene, polysi-
loxane, polyvinyl chloride, polyacrylonnitrile, and 
polystyrene (9,10). Compared to glass, plastic mini-
mizes exposure to biohazardous material follow-
ing breakage, has a greater shock resistance, toler-
ates higher centrifugation speeds, weighs less, has 
excellent dimensional precision, and is more easily 











Figure 1. Components of an evacuated blood collection tube.
Reprinted from Clinical Biochemistry, 43 (1-2), Bowen RAR, Hor-
tin GL, Csako G, Otanez O, Remaley AT. Impact of blood collec-
tion devices on clinical chemistry assays, pages 4-25, 2010, with 
permission from Elsevier.
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However, plastic has greater gas permeability com-
pared to glass tubes (18). There have been numer-
ous studies comparing glass and plastic tubes for 
use in chemistry (4,19), endocrinology (19), molec-
ular testing (20), serology (21), and coagulation 
testing (10,19). Despite small statistically significant 
differences between plastic and glass tube analyte 
determinations, none is considered clinically sig-
nificant. PET, a commonly used plastic in the man-
ufacture of BCTs is unbreakable and maintains a 
vacuum for a prolonged time (22). PP, another 
commonly used plastic, has a lower water perme-
ability, allowing it to retain liquid anticoagulant 
volume and concentration (22). Thus, PET tubes 
have double-walls to minimize evaporation, espe-
cially for coagulation-based tests (22); the internal 
PP layer protects against citrate solution evapora-
tion, whereas the outer PET layer is more transpar-
ent, allowing easier visualization of tube fill levels. 
The PP plus PET combination improves shelf life 
and anticoagulant volume retention (22).
Plastic tubes generally have a hydrophobic surface 
and do not efficiently activate the coagulation 
process (23); clots formed on the plastic surfaces of 
tubes are gelatinous compared to clots formed in 
glass tubes (23). Further, blood does not flow 
smoothly over hydrophobic plastic surfaces, which 
can result in the adherence of platelets, fibrin, or 
clotted blood on the tube walls (23). This can make 
it difficult to cleanly separate serum from the 
blood clot by centrifugation, especially for micro-
collection tubes or during centrifugation of vacu-
um tubes. The hydrophilicity of plastic surfaces 
can be increased by using plasma-enhanced 
chemical vapor deposition to introduce polar func-
tional groups (24). Alternatively, the interior plastic 
surfaces can be coated with SFs, water-soluble 
polymers, or hydrophilic-hydrophobic copolymers 
(23), although SFs may dissolve in blood and inter-
fere with clinical tests (8). There are ongoing ef-
forts to incorporate SFs into plastic tubes to pre-
vent exudation into blood specimens (9,10).
Rubber stoppers
Rubber stoppers are routinely color-coded accord-
ing to anticoagulant type and the presence of a 
separator gel. The stopper should be readily pen-
etrated by a needle and self-seal upon needle re-
moval (23), maintaining the internal pressure dif-
ferential (23). Suitable materials include polychlo-
roprene, silicone, styrene butadiene, isobutylene-
isopropene, chlorinated ethylene-propylene co-
polymers, and isobutylene-isoprene rubber 
(23,25,26). Butyl rubber, a copolymer of isobuty-
lene and isoprene, and halogenated butyl rubber 
are commonly used materials (23,25,26); butyl rub-
ber exhibits superior air and moisture impermea-
bility, superior resistance to chemical attack and 
heat resistance, and good processability (25,26). To 
reduce the potential for splatter from the blood 
specimen when the rubber stoppers are removed 
from the collection tube, a stopper shield is used 
(e.g. Hemogard™). The stopper shield can be made 
from thermoplastic materials, such as polyethyl-
ene, polypropylene, and polyvinylchloride (8,26). 
Discrepancies in the bioavailability and bioequiva-
lence of tests for blood specimens collected into 
tubes whose rubber stoppers containing the plas-
ticizer tris-(2-butoxyethyl)-phosphate (TBEP) have 
been reported (27). TBEP, which is used to make 
stoppers soft, displaces certain drugs from plas-
ma-protein binding sites, such as the α1-acid glyc-
oprotein (28), resulting in increased drug uptake 
by red blood cells (RBCs), thus artificially lowering 
serum or plasma levels. TBEP has been reported to 
alter the drug distribution of quinidine, pro-
pranolol, lidocaine, tricyclic antidepressants, and 
several phenothiazine drugs, including fluphena-
zine and chlorpromazine (29). Therefore, tube 
manufacturers have decreased or eliminated pro-
duction of rubber stoppers containing TBEP (27). 
Janknegt et al. (30) have demonstrated that rubber 
stoppers made without TBEP do not interfere with 
therapeutic drug monitoring. However, other stop-
per components can also pose problems. Curry et 
al. (31) reviewed how materials from elastomeric 
closures, including butyl rubber stoppers, can con-
taminate specimens with these container closures. 
Metals such as calcium, aluminum, magnesium, 
and zinc are used to manufacture rubber stoppers; 
it is essential that these metals are not extracted 
upon contact with blood (32); specially formulated 
rubber stoppers have been made to limit divalent 
cation leaching (33). Sulfur, sulfur-containing vul-
canization accelerators, fatty acids, and peroxides 
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in stoppers can also potentially affect lab tests; 
therefore, most stoppers are manufactured with 
low-extractable rubber or have been modified to 
minimize leaching into the blood specimens (29). 
The complete filling of BCTs dilutes any leached 
material and helps reduce the effects (34). Further, 
specimens in tubes with rubber stoppers should 
be stored at low temperatures (2 °C to 8 °C) and in 
the upright position to minimize leaching (34).
Stopper lubricants
Lubricants, such as silicone oils, fluids, and glycer-
ol, facilitate the insertion and removal of stoppers 
(6,9,10). Lubricants minimize red blood cell and clot 
adherence to stoppers in order to prevent serum 
or plasma contamination (6,9,10). However, glycer-
ol should not be used to lubricate stoppers used 
for specimens measuring glycerol or triglyceride 
when a non-glycerol blank assay is used (35). Sili-
conized stoppers are generally preferred because 
they are less likely to interfere with assays, al-
though silicone may falsely elevate ionized mag-
nesium and total triiodothyronine levels (7) and 
may confound peaks during mass spectrometry 
(MS) analysis and peak interpretation (36).
Anticoagulants
Although serum is used for most assays, plasma is 
a useful alternative due to its rapid processing 
time. Plasma, which contains fibrinogen and other 
clotting factors, has a higher viscosity and total 
protein content than serum (37). Serum has a high-
er concentration of thromboglobulins, potassium, 
activation peptides for coagulation factors, plate-
let factor 4, and platelet components released dur-
ing platelet activation (37). Anticoagulants used to 
preserve analytes may interfere with other analyte 
determinations when using plasma (38). Ethylene-
diaminetetraacetic acid (EDTA), heparin, and cit-
rate are the most commonly used anticoagulants 
(39-41).
Potassium EDTA (Table 1), an anticoagulant and 
chelating agent, interferes with calcium assays and 
clot generation (42), but it is preferred for hematol-
ogy testing. EDTA binds the metallic ions euro-
pium (immunoassay reagent), zinc, and magnesi-
um (enzyme cofactors for immunoassay reagents 
such as alkaline phosphatase) (43). Insufficient 
sample volumes produce relatively elevated EDTA 
levels, which can increase the chelation of magne-
sium and zinc, and can then affect reagent en-
zymes used for signal generation, such as alkaline 
phosphatase (43). Reagent antibodies recognize 
divalent cation complex binding sites on proteins; 
thus, decreased calcium and magnesium levels 
may induce conformational changes that decrease 
antibody binding (43).
Heparin salts (typically from porcine intestinal mu-
cosa) are also extensively used as anticoagulants 
in BCTs (Table 1) (44). Heparin complexes with and 
induces a conformational change of antithrombin 
III to accelerate the inhibition of thrombin and Fac-
tor Xa (35), which prevents thrombin activation 
and the generation of fibrin from fibrinogen. Since 
heparin binds electrolytes and changes the con-
centration of bound and free ions (45), manufac-
turers have created electrolyte-balanced formula-
tions (45). However, heparin can interfere with a 
variety of clinical assays. Specimens assayed with 
Dimension™ Vista 1500 (Siemens Healthcare Diag-
nostic, Newark, DE, USA) may produce negative 
anion gaps due to heparin interference with chlo-
ride electrode membranes (unpublished observa-
tion). Heparin also slows some antibody-antigen 
reaction rates (46), particularly during the precipi-
tation step in second-antibody systems, although 
this problem can be avoided with the use of solid-
phase systems (47). Heparin should also be avoid-
ed in cryoprotein investigations since it precipi-
tates cryofibrinogen (43,47). Exogenously adminis-
tered heparin alters serum thyroid hormone levels 
(43,47). Falsely low albumin levels have been ob-
served when heparinized tubes have been used 
on hemodialysis patients (48). It is has been pro-
posed that heparin inhibits the binding of bromo-
cresol green to albumin, leading to less colorimet-
ric complex formation (48). Proteomic studies 
show that heparinized plasma causes non-specific 
protein binding, which influences the separation 
and MS of peptides (49). Recently, Lippi et al. (50) 
demonstrated that incomplete filling of lithium 
heparin tubes produced significantly higher creat-
ine kinase and γ-glutamyltransferase activity on a 
Unicel DxC 800 analyzer.
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Stoper color*
(tube wall material) Additive(s)
Amount/
concentration




Clot activator with separator gel
Clot activator with separator gel
Clot activator with separator gel
Orange (plastic) Thrombin with separator gel 10-15 National Institute of Health units per tube (10)
Light blue (plastic) Citrate, trisodium (liquid additive) (1 part additive to 9 parts of blood) 0.109 M (3.2%) or 0.129 M (3.8%)
Dark green (plastic) Heparin, sodium (dry additive) 10–30 USP units/mL blood
Light green (plastic) Heparin, lithium (dry additive) with separator gel 10–30 USP units/mL blood
Green/gray Heparin, lithium (dry additive) with separator gel 10–30 USP units/mL blood
Lavender (plastic) EDTA, dipotassium (dry additive) 1.5–2.2 g/L blood
Lavender (plastic) EDTA, tripotassium (liquid additive) 1.5–2.2 g/L blood
Lavender (plastic) EDTA, disodium (dry additive) 1.4–2.0 g/L blood
Gray (plastic) Sodium fluoride/potassium Oxalate (dry additive) Sodium fluoride: 2.5 g/L blood; potassium oxalate: 2.0 g/L blood
Gray (plastic) Sodium fluoride/sodium EDTA (dry additive) Sodium fluoride: 2.5 g/L blood; sodium EDTA: 1.5 g/L blood
Gray (plastic) Lithium iodoacetate Iodoacetate: ~2 g/L blood
Yellow (glass) Acid Citrate Dextrose (ACD) – solution A(1 part additive to 5.67 parts of blood)
Citrate, disodium, 22.0 g/L; citric acid, 8.0 
g/L; dextrose, 24.5 g/L
Yellow (glass) Acid Citrate Dextrose (ACD) – solution B(1 part additive to 3 parts of blood)
Citrate, disodium, 13.2 g/L; citric acid, 4.8 
g/L; dextrose, 14.7 g/L
Royal blue (glass) 
(with red band on label) None
Royal blue (glass) (with 
lavender band on label) EDTA, dipotassium (dry additive) ~1.8 g/L blood
Tan (plastic) EDTA, dipotassium (dry additive) 1.8 g/L blood
Black (glass) Sodium citrate 0.105 M (~3.2%)
Clear (plastic) None
Red/LightGray (plastic) None
*Single or multiple stopper color combinations may vary from different tube manufacturers.
Table modified from the Clinical and Laboratory Standards Institute: Evacuated Tubes and Additives for Blood Specimen 
Collection; Approved standard H3-A4 (40) and information from Young et al. (41) and in the BD website (42). Reprinted from 
Clinical Biochemistry, 31 (1-2), Bowen RAR, Hortin GL, Csako G, Otanez O, Remaley AT. Impact of blood collection devices on clinical 
chemistry assays, pages 4-25, 2010, with permission from Elsevier.
Table 1. Evacuated blood collection tube stopper color and additives.
Trisodium citrate in a 3.2% (109 mmol/L) or 3.8% 
(129 mmol/L) solution is preferred for coagulation 
testing (Table 1) (51). It can inhibit both aspartate 
aminotransferase and alkaline phosphatase by the 
chelation of cations (51). Sodium citrate, which is 
used in acid citrate dextrose and citrate theophyl-
line adenosine dipyrridamole (51), inhibits platelet 
activation and is used to measure plasma levels of 
platelet-derived components.
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Potassium oxalate, another calcium-chelating anti-
coagulant (Table 1) often combined with antiglyc-
olyitc agents (sodium fluoride and sodium iodoac-
etate) can actually decrease hematocrits by as 
much as 10% by drawing water from cells into 
plasma (51). Oxalate can also inhibit several en-
zymes, such an amylase, lactate dehydrogenase, 
and acid and alkaline phosphatase (51).
Sodium fluoride (Table 1) inhibits the glycolytic en-
zyme enolase and is used to limit the ex vivo con-
sumption of glucose by cells in a collected blood 
specimen (51). However, in fluoridated, non-sepa-
rated blood samples, glucose is still metabolized 
at approximately 5% to 7% per hour at room tem-
perature because upstream enzymes continue to 
convert it to glucose-6-phosphate (52). Hence, 
complete inhibition of glycolysis in fluoride-con-
taining tubes can take up to 4 hours at room tem-
perature with a normal blood cell count (53). Fluor-
idated tubes can affect diabetes diagnosis, which 
uses fixed plasma glucose levels established using 
blood that was iced, centrifuged, and had the plas-
ma removed (54). In fact, the American Diabetes 
Association no longer recommends using sodium 
fluoride only to inhibit in vitro glycolysis (54). A BCT 
with EDTA and fluoride in a citrate buffer (pH < 5.9) 
has been proposed to preserve glucose concen-
trations due to its immediate inhibition of glycoly-
sis (53). Sodium fluoride may be unsuitable for en-
zymatic immunoassays because of its enzyme in-
hibitory activity (51). Fluoride may also interfere 
with electrolyte measurements by altering cell 
membrane permeability (51) and promoting 
hemolysis by red blood cell ATP with subsequent 
potassium efflux (51). Iodoacetate preserves glu-
cose concentrations by inhibiting glyceraldehyde-
3-phosphosphate dehydrogenase, but it can inter-
fere with the measurement of glucose, sodium, 
potassium, chloride, and lactate dehydrogenase 
measurements and can cause hemolysis (51).
Although anticoagulants and antiglycolytics can 
be unsuitable for certain assays, assay manufactur-
ers do not always specify the plasma sources used 
to validate their tests. Consequently, it is important 
that clinical laboratories assess tube performance 
with their particular assays, instruments, and plat-
forms. Tube manufacturers’ fill-volume recom-
mendations should be followed to ensure proper 
additive to blood ratios and minimize assay inter-
ference and resultant laboratory errors, repeat 
testing, and unnecessary troubleshooting.
Separator gels
Separator gels are used to separate serum from 
clotted whole blood or plasma from cells (55). In 
this regard, serum separator tubes (SST) are easy 
to use, require short processing times, yield higher 
serum levels, limit hazardous aerosolization, re-
quire only one centrifugation step, allow primary 
tube sampling, and require a single label (55).
During centrifugation, the thixotropic gel used in 
these tubes lodges between packed cells and the 
top serum layer (56). The position of the gel after 
centrifugation is influenced by many tube charac-
teristics, such as specific gravity, yield stress, vis-
cosity, density, and tube material. It can also be af-
fected by temperature, centrifugation speed, ac-
celeration and deceleration, storage, and patient 
factors, such as heparin therapy, low hematocrit, 
elevated plasma protein, and serum/plasma spe-
cific gravity (57). Polymeric gels affect viscosity, 
density, and other physical properties. Separator 
gels are typically made from viscous liquids, fillers, 
or tackifiers with substances like dibenzylidene 
sorbitol as a gelling agent (23). The inner tube sur-
face may have a hydrophobic coating to ensure 
separator gel adherence and a complete barrier to 
prevent mixing between RBCs and serum/plasma 
(9,10). Because the serum/plasma specific gravity 
ranges from 1.026 to 1.031 g/cm3, and the clot spe-
cific gravity ranges from 1.092 to 1.095 g/cm3, the 
separator gel specific gravity should ideally be 
within 1.03 to 1.09 g/cm3 (58). If the serum/plasma 
specific gravity is elevated due to hyperproteine-
mia or radio-contrast dye, the serum may not float 
above the gel (57). Fatas et al. (58) showed that the 
specific gravity is a more important factor than vis-
cosity affecting improper BCT gel separation. In 
addition, Faught et al. (59) showed differences in 
separator gel specific gravity in different BCTs and 
between some tube lots.
Several reports of gels affecting analyte concen-
trations have been published. Hydrophobic drugs, 
such as phenytoin, phenobarbitol, carbamazepine, 
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quinidine, and lidocaine, can adsorb onto hydro-
phobic separator gels and lead to a decrease in se-
rum drug concentrations by as much as 20% to 
50% after 24 hours at 4 °C (60,61). Organochlorine, 
polychlorinated biphenyl, and progesterone levels 
may also be significantly reduced (47). A small but 
statistically significant difference in myoglobin and 
CK-MB levels has been reported between tubes 
with and without separator gels (5). Interestingly, 
newer separator gels (e.g. polydimethylsiloxane-
polyethylene oxide copolymers) that minimize 
drug and analyte adsorption have been developed 
(e.g., the BD SST II™ tube) (9,10,62). Recently, RBCs 
have been observed to surpass the separator gel 
barrier in plasma and serum tubes increasing the 
plasma/serum potassium levels (63). Separator gels 
may also release materials (e.g., gel pieces and sili-
cone oil) into the specimens and spuriously inter-
fere with assays, sample probes, tubes and cu-
vettes, solid-phase immunoassay systems, and 
electrode surfaces (47,64); the rate of degradation 
and release may be increased by improper storage 
or extreme temperatures (47). Recently, Shi et al. 
(65) demonstrated that the separator gel compo-
nents in some types of BCTs (i.e., SST and lithium 
heparin plasma separator tubes) from a specific 
tube manufacturer were the source of interference 
in the quantitation of serum testosterone levels 
using liquid chromatography-tandem MS. The in-
terference increased according to the length of 
storage of serum in the tubes and was more pro-
nounced with specimens containing low testoster-
one levels (65). Modifications of the assay and liq-
uid chromatography-tandem MS parameters did 
not resolve the tube interference problem with 
the quantitation of serum testosterone levels (65). 
Thus, new technologies applied in the clinical lab-
oratory to determine analyte concentrations can 
be significantly affected by BCTs components such 
as the separator gel. Ideally, separator gels should 
maintain uniform chemical and physical proper-
ties for the intended period of use and be inert to 
the specimens collected in BCTs.
Clot activators and water-soluble agents
Plastic tubes require clot activators that use either 
intrinsic or extrinsic pathways to ensure rapid and 
dense clot formation (10). Clot activation by the in-
trinsic pathway is surface-dependent and a greater 
density of activating surface sites speeds clotting 
time. Siliceous substances (e.g., glass, silica, kaolin, 
bentonite, diatomaceous earth) accelerate clot for-
mation through contact activation (23), but partic-
ulate clot activators work relatively slowly (30 to 60 
minutes) (10). The amount of clot activator varies 
by manufacturer (23). Clot activators also diminish 
latent fibrin formation in the separated serum (47).
Clot activation by the extrinsic pathway, coagula-
tion initiated by adding substances extrinsic to 
blood, is biochemical (e.g., ellagic acid, thrombin, 
snake venoms, thromboplastin) and concentra-
tion-dependent (10). Although these clot activa-
tors produce rapid clotting (10 to 20 minutes), the 
clots formed are gelatinous and do not easily sep-
arate from serum (10). Clot activators can be added 
to tubes by adding small beads or paper coated 
discs, or they can be sprayed on interior tube sur-
faces with a carrier (e.g., polyvinylpyrrolidone 
(PVP), carboxymethyl cellulose, polyvinyl alcohol, 
and polyethylene oxide) (10,23). These carriers al-
low rapid clot activator suspension into blood so 
that the carriers dissolve into both serum and clots 
as the clotting is initiated (23). PVP and water-solu-
ble SFs also release clot activators into blood spec-
imens to reduce the need for mixing (23). BD has 
recently released a serum tube containing 
thrombin (rapid serum tubes (RSTTM); Table 1, or-
ange stopper) for rapid clot activation (within 5 
minutes) (42). Dimeski et al. (66) demonstrated that 
the use of RST tubes would not be appropriate for 
patients on high-dose heparin or warfarin therapy 
since latent clot formation in the tube may clog in-
strument probes and produce erroneous test re-
sults. Based on these findings, it is clear that addi-
tional studies are needed to ensure that the RST 
tubes give clinically equivalent results to other 
commercially available serum tubes, especially for 
partially filled tubes of blood.
Some clot activators are problematic in that they 
must be thoroughly mixed to allow complete pel-
leting with the clot. If soluble fibrin clots form, they 
can interfere with pipetting device accuracy or in 
solid-phase binding in immunoassays (67). To limit 
these problems, plasma gas may be used to intro-
duce heteroatoms (non-carbon and hydrogen at-
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oms in the backbone of the molecular structure) 
to the tube wall surface to accelerate clotting with-
out contaminating the serum or clot with binders 
or activators (24).
Various studies have revealed the impact of clot 
activators on laboratory test performance. Samp-
son et al. (68) showed that silica and silicone SF are 
associated with elevated lithium concentrations 
when using the Lytening 2Z (Lytening West Pea-
body, MA, USA) ion-specific electrode analyzer. 
The clot activators or silicone SFs can interact with 
ion-specific analyzer membranes, which increase 
the measured voltage and falsely elevate serum 
lithium ion concentration. Clot activators can also 
falsely elevate serum testosterone measurements 
(69), but changing the ion pair eliminates this prob-
lem (69). Proteome analysis by MS may also be al-
tered by clot activators (70). Silica and silicate clot 
activators, when sprayed onto plastic tubes, induc-
es the release of pro-, active, and complexed ma-
trix metalloproteinases (71). Recently, it was shown 
that ficolin-1 and ficolin-2 levels, a group of pro-
teins that can activate the complement pathway, 
and their binding capacities were significantly af-
fected, presumably, by the silicate material in SST 
tubes (72). Thus, it is critical that the optimal 
amounts and composition of clot activators and 
water-soluble agents be determined and consist-
ently added to different types and sizes of BCTs in 
order for these substances to function properly 
without adversely affecting the quality of the 
blood specimens and test results.
Surfactants
SFs are commonly used to decrease non-specific 
adsorption, but they must be carefully selected 
and optimized for immunoassays since, at high 
concentrations, they may cause the loss of anti-
bodies passively adsorbed onto the solid support 
beads used in immunoassays (73). Commercially 
available tubes contain a variety of SFs (7,8,10) that 
improve blood flow, distribute clot activator, and 
prevent proteins, RBCs, and platelets from adsorb-
ing to tube walls (10).
Silicone SF-coated tubes have been shown to in-
terfere with ion-specific electrode measurement 
of ionized magnesium and lithium (7,68). Silicone 
SFs seems to interact with ion-specific electrode 
membranes to increase the measured voltage dur-
ing magnesium and lithium determinations (7,68). 
In addition, water-soluble silicone polymer coat-
ings in separator tubes can physically mask anti-
bodies and alter avidin-biotin binding reactions in 
immunoradiometric assays (74).
Bowen et al. (7) demonstrated that the nonionic 
polydimethylsiloxane-polyethylene oxide and 
polypropylene oxide graft copolymer SF, Silwet™ 
L-720 (Figure 2; OSI Specialities, Danbury, CT, USA; 
75), in BD SST™ tubes falsely elevates triiodothyro-
nine in a dose-dependent manner by causing the 
desorption of captured antibodies from the solid 
phase used in immunoassays (7,8). Competitive 
immunoassays (e.g., vitamin B12) and non-compet-
itive immunoassays (e.g., cancer antigen 15-3) are 
also affected by Silwet L-720, but the mechanism is 
unclear (7).
Figure 2. Silwet™ silicone surfactant. A) general molecular 
structure and B) schematic structure with polyether (polyethyl-
ene oxide and polypropylene oxide) attached (via hydrosilation 
reaction) to the polydimethylsiloxane backbone; x, y, m, n are 
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Due to immunoassay interference, BD reformulat-
ed their tubes to reduce SF levels (7). Morovat et al. 
(76) have shown statistically significant but clini-
cally insignificant biases in immunoassay results 
using these reformulated tubes. Yet, in this study, 
the control tubes were coated with the problem-
atic SF. Wang et al. (77) reported that the reformu-
lated tubes produced clinically significant biased 
results for free triiodothyronine and free thyroxine. 
Interestingly, Silwet L-720 and other types of Silwet 
surfactants can be used in separator gel formula-
tions, which may account for the clinically signifi-
cant biased thyroid hormone test results with the 
reformulated tubes stated above (75).
Further studies have examined whether additives 
supply molecules that may interfere with MS 
peaks. Drake et al. (36) showed that seven of the 
eleven tubes tested contained various compo-
nents, such as SF and polyvinylpyrrolidone, which 
produced multiple MS signals in the m/z range of 
1,000 to 3,000. These tube additive peaks compli-
cate and compromise mass spectra interpretation 
in the low molecular mass range, particularly for 
MALDI or SELDI techniques (36). Tube additives 
may also affect the ionization process during liq-
uid chromatography-MS analysis, thereby sup-
pressing metabolite ionization. Yin et al. (78) re-
cently reported that five different S-Monovettes™ 
(Sarstedt Newton, NC, USA) BCT additives pro-
duced chemical noise in the mass spectra that in-
terfered with metabolic profiling. Thus, an initial 
step in MS investigations should be the examina-
tion of BCTs.
SF detergent properties can also alter cell mem-
brane permeability and lipophilic structures. A 
study showed that SFs in tubes affected free fatty 
acid concentrations in specimens rather than in-
terfere with their analytical detection (79). Thus, 
producing BCTs with SF that do not contaminate 
the blood specimens and cause assay interferenc-
es would be ideal.
Order of draw
The importance of the order of draw in obtaining 
accurate laboratory tests has been known for 
many decades. Calam and Cooper (80) demon-
strated that the initial drawing of blood into potas-
sium-EDTA tubes falsely decreased and increased 
the calcium and potassium values, respectively, in 
blood collected into subsequent tubes containing 
no anticoagulants (80). These findings prompted 
the development of Clinical and Laboratory Stand-
ards Institute (CLSI) guidelines to standardize tube 
sequence and syringe use for blood collection to 
minimize carryover of tube additives (81). When 
laboratories switched from glass to plastic tubes, 
the CLSI order of draw guideline changed because 
plastic serum tubes were considered equivalent to 
gel separator tubes with clot activators (81). The 
current CLSI guideline for glass and plastic tubes 
order of draw is as follows: blood culture tubes; so-
dium citrate tubes; serum tubes with and without 
clot activator and with or without gel separator; 
heparin tubes with or without gel separator; EDTA 
tubes; acid citrate dextrose containing tubes; and 
glycolytic inhibitor (fluoride, iodoacetate) tubes 
(81). However, the use of order of draw has recently 
been questioned and studies by Salvagno et al. 
(82) have demonstrated negligible effects of the 
order of draw on sample quality for some routine 
chemistry tests. Nevertheless, an extensive study 
with more analytes is warranted. Tube manufac-
turers color-code tube closures for easy identifica-
tion of tube additives. Laboratorians must under-
stand associated additives, proper order of draw, 
and carryover effects of additives on clinical as-
says.
Protease inhibitors
Protease inhibitors are among the most abundant 
plasma protein components (83), far outnumber-
ing active proteases except where activation oc-
curs by surfaces or other stimuli. Chelating agents, 
such as EDTA and citrate, do not directly inhibit 
serine proteases, but they do limit the activation 
of proteases in the coagulation system by interfer-
ing with calcium-mediated surface binding and by 
allowing inhibitors to dominate. Direct inhibitors 
of thrombin or coagulation factor Xa serve as al-
ternative anticoagulants, but they have not 
achieved widespread use because of cost (84). 
Such products, however, can increase protein sta-
bility and allow chemistry and hematology tests 
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on a single specimen. Small bioactive peptides 
such as parathyroid hormone and insulin are more 
stable in EDTA-anticoagulated plasma compared 
to citrate-anticoagulated plasma or serum (85). 
Aprotinin increases the stability of brain-type 
natriuretic peptides (86); some reference laborato-
ries recommend the collection of specimens for 
bioactive peptide analysis in tubes containing 
aprotinin or other protease inhibitors. Many pep-
tides, such as glucagon-like peptide 1, undergo 
rapid cleavage by the exopeptidase dipeptidyl 
peptidase IV (87), and thus collection tubes must 
contain exopeptidase inhibitors to recover the in-
tact peptide. EDTA-containing tubes are generally 
recommended for proteomic analyses to minimize 
protein component changes (88); small peptide 
components can also undergo rapid degradation 
by exopeptidases (89). However, addition of chem-
ically reactive protease inhibitors, such as sulfonyl 
halides, can covalently modify proteins (89). An al-
ternative approach is to inhibit protease activity 
by decreasing pH (89). In general, small peptides 
are frequently less stable than proteins since pro-
teases sequestered in an α2-macroglobulin inhibi-
tor retain peptidolytic activity even though they 
are sterically hindered from cleaving full-size pro-
teins (90); further, peptides lack a globular struc-
ture and are more accessible to exopeptidase ac-
tion. Although endogenous protease inhibitors are 
quite abundant in plasma, most are mainly against 
serine dependent endoproteases and exhibit rela-
tively little activity against exopeptidases. There-
fore, the addition of exogenous, low molecular 
weight protein inhibitors or small synthetic com-
pounds to a blood specimen is often used to sta-
bilize samples.
Protease activity may be accentuated by the re-
lease of intracellular proteases from white or RBCs. 
For example, insulin is substantially less stable in 
hemolyzed blood because of the thiol proteases 
from RBCs (91). The use of protease inhibitors has a 
limited effect on the recovery of chemokines and 
cytokines from plasma, but the rapid processing 
of blood can limit this problem because most cy-
tokines and chemokines are degraded by intracel-
lular protease (92).
The addition of exogenous protease inhibitors de-
pends on the intended use of specimens. Because 
there is wide variability in protein and peptide sta-
bility, each laboratory should analyze the stability 
of components of interest; where protein or pep-
tide stability problems are identified, protease in-
hibitors should be considered. Blood collection 
systems (e.g., BD P100™) containing a cocktail of 
protease inhibitors that enable preservation of 
plasma proteins for proteomic investigation have 
been developed (42).
Recommendations
Prevention of pre-analytical errors from BCT addi-
tives remains an ongoing problem for tube and as-
say manufacturers and ultimately affects the abili-
ty of clinical laboratories to produce accurate re-
sults. Any new or modified blood collection prod-
uct should ideally be thoroughly evaluated for any 
potential problems inherently caused in the down-
stream processing and analysis of specimens. BCT 
manufacturers should also consider evaluating 
their products under conditions of reduced speci-
men volumes, extended contact times, and long-
term storage. Because it is not possible for manu-
facturers to assess the impact of their tubes on all 
assay platforms, it is important that they establish 
close working relationships with their customers 
and should consider developing a surveillance 
program to quickly identify problems. Similarly, 
manufacturers of assays and instrument platforms 
should ideally verify the performance of their as-
says with a wide variety of BCTs on the market and 
on different lots of the same tube type. Reference 
interval studies performed on older instruments 
or tubes no longer in use should be repeated us-
ing materials and conditions that are consistent 
with current use.
Blood collection device problems may go unno-
ticed by laboratorians since routine quality control 
(QC) practice typically does not assess all aspects 
of laboratory testing from blood collection, includ-
ing specimen processing, analytical testing, and 
test reporting (7,8). Proficiency testing programs, 
which do not require blood collection, also fail to 
detect blood collection device problems (7,8). 
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Hence, QC and proficiency testing specimens in 
clinical laboratories are analyzed but not proc-
essed as patient specimens are. Although QC spec-
imens are typically non-commutable with native 
patient specimens because the QC matrices are 
usually altered by manufacturing processes from 
that of native specimens, the comparison of con-
trol sera results from specimens exposed and non-
exposed to BCTs could potentially reveal the ad-
verse effects of additives (7,8,93). This could be 
done by clinical laboratories or perhaps by tube 
manufacturers by exposing QC sera to BCTs on a 
lot-by-lot basis. When laboratorians change the 
tubes they use, they should also perform a com-
parative tube evaluation (94); this tube comparison 
study should be similar to the one described for 
method comparison studies, using the CLSI EP9-A 
guideline (95). In addition to contacting tube man-
ufacturers, tube-related issues should also be re-
ported to regulatory agencies (i.e., Food and Drug 
Administration) via MedWatch in the United States 
and the Medicines Healthcare Products Authority 
in the United Kingdom. Finally, the routine evalua-
tion of BCTs by clinical laboratories should be in-
corporated into QC plans based on risk manage-
ment to help prevent or detect tube-related errors 
and enhance the quality of the test results (96).
The BD Diagnostics preanalytical division has de-
veloped a program through an Instrument Com-
pany Liaison to work with assay manufacturers to 
identify and eliminate and/or reduce tube-related 
assay problems prior to products being commer-
cialized (97, 98, 99). A CLSI guideline is available for 
tube manufacturers, in vitro diagnostic manufac-
turers, and clinical laboratories for verification and 
validation of venous and capillary BCTs for chemis-
try, immunochemistry, hematology, and coagula-
tion (99,100).
Conclusions
Although current BCTs largely work as designed 
and are therefore often taken for granted, it is im-
portant that laboratorians become aware of the 
potential problems that they can cause in the anal-
ysis of specimens. BCTs are medical devices and, as 
such, have inherent limitations. When improperly 
used or because of problems related to their man-
ufacturing, BCT-related interferences in test results 
can adversely influence patient outcomes, de-
crease laboratory efficiency, delay test results, and 
increase the cost per test due to recollection and 
retesting. Thus, optimization and standardization 
of BCTs are vital for the reliable test analysis. Be-
cause laboratory test result quality ultimately de-
pends on specimen integrity, tube manufacturers, 
in vitro diagnostic companies, and laboratorians 
should all remain vigilant in protecting against the 
adverse effects of BCT problems on clinical labora-
tory assays.
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